LB Pharmaceuticals found enough investor interest to boost the size of its IPO, which will finance clinical trials in schizophrenia and bipolar depression. The biotech has modified an old Sanofi drug with changes intended to reduce side effects and allow less frequent dosing.
The post LB Pharma Pushes the Biotech IPO Window Open, Bagging $285M for Key Schizophrenia Drug Trial appeared first on MedCity News.
